Track topics on Twitter Track topics that are important to you
Today's Daily Dose brings you news about BioCryst Pharma's stock offering; AxoGen and Blueprint Medicines' strong Q2 financial results; positive results of RXi Pharmaceuticals' phase I/II trial with RXI-109 for retinal scarring and reverse stock split of Synthetic Biologics.
Original Article: ARQL Lifts 2018 Outlook, AXGN Q2 Revenue Up 36%, RXII Catches EyesNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...